BioSpace News Archive

Business

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”

September 7, 2018
·
3 min read
·
Mark Terry
Business

Movers and Shakers for Sept. 10

Let’s take a look at who made a splash in the pharma and biotech world the past week.

September 7, 2018
·
5 min read
·
Alex Keown
Genetown

28-7 Therapeutics Raises $65 Million to Advance Tumor Suppressor Research

Twentyeight-Seven Therapeutics (28-7), announced it had completed a $65 million Series A financing. It was co-led by founding investor MPM Capital and Novartis Venture Fund. Joining them were Johnson & Johnson Innovation – JJDC, Vertex Ventures, Longwood Fund, and Astellas Venture Management.

September 7, 2018
·
3 min read
·
Mark Terry
Business

Probiodrug Reports Financial Results for H1 2018 and Corporate Update

Probiodrug AG today announces its financial results for the first six months of 2018 ending June 30.

September 7, 2018
·
10 min read
We Want to Hear from You! Top Life Sciences Trends

As a valued member of our BioSpace community, we are eager to hear more from you and other readers.

September 7, 2018
·
1 min read
·
Editorial Staff
FDA

ITF Secures FDA Approval for Liquid Riluzole for ALS Patients

Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.

September 7, 2018
·
2 min read
·
Alex Keown
Business

Zealand Abandons Sanofi Diabetes Drug in $205 Million Deal with Royalty Pharma

Copenhagen-based Zealand Pharma is selling future royalty streams and $85 million in potential commercial milestones for two diabetes drugs, Soliqua/Suliqua and Lyxumia/Adlyxin, to New York-based Royalty Pharma.

September 7, 2018
·
3 min read
·
Mark Terry
Business

Bone Therapeutics announces H1 results for 2018

Bone Therapeutics announces H1 results for 2018

September 7, 2018
·
6 min read
Business

Amid Akcea Layoffs, FCS Patient Advocacy Group Demands FDA Reconsider Waylivra

A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.

September 7, 2018
·
3 min read
·
Alex Keown
6 Important Reasons You Should Always Take Your Paid Vacation Time

Neglecting vacation time can have serious consequences, not only to your own personal health and happiness levels, but also a large-scale financial and economic impact.

September 7, 2018
·
3 min read
·
Editorial Staff